Diabetic Complications Research Center, Division of Traditional Korean Medicine Integrated Research, Korea Institute of Oriental Medicine, Daejeon, 305-811, Korea.
Arch Pharm Res. 2010 Sep;33(9):1317-23. doi: 10.1007/s12272-010-0904-z. Epub 2010 Oct 9.
Five compounds previously known structures, scopoletin (1), northalifoline (2), stigmast-4-en-3-one (3), tiliroside (4), and oplopanone (5) were obtained from the flower buds of Magnolia fargesii using chromatographic separation methods. The structures of 1-5 were identified by the interpretation of their spectroscopic data including 1D- and 2D-NMR as well as by comparison with reported values. Three compounds 1-3 were found from M. fargesii for the first time in this study. All the isolates (1-5) were subjected to in vitro bioassays to evaluate the inhibitory activity on advanced glycation end products formation and rat lens aldose reductase (RLAR). Compound 1 showed a remarkable inhibitory activity on advanced glycation end products formation with IC(50) value of 2.93 μM (aminoguanidine: 961 μM), and showed a significant RLAR inhibitory activity with IC(50) value of 22.5 μM (3.3-tetramethyleneglutaric acid: 28.7 μM). Compound 4 exhibited potent inhibitory activity against RLAR (IC(50) = 14.9 μM). In the further experiment ex vivo, cataractogenesis of rat lenses induced with xylose was significantly inhibited by compound 1 treatment.
从 Magnolia fargesii 的花蕾中,采用色谱分离方法得到了 5 种已知结构的化合物:东莨菪内酯(1)、北美黄连碱(2)、豆甾-4-烯-3-酮(3)、芫花素(4)和吴茱萸碱(5)。通过解析其光谱数据(包括 1D-和 2D-NMR)以及与文献值进行比较,确定了 1-5 的结构。在本研究中,化合物 1-3 首次从 M. fargesii 中分离得到。所有分离得到的化合物(1-5)均进行了体外生物活性测定,以评估其对晚期糖基化终产物形成和大鼠晶状体醛糖还原酶(RLAR)的抑制活性。化合物 1 对晚期糖基化终产物形成具有显著的抑制活性,IC50 值为 2.93 μM(氨基胍:961 μM),对 RLAR 具有显著的抑制活性,IC50 值为 22.5 μM(3.3-四亚甲基戊二酸:28.7 μM)。化合物 4 对 RLAR 具有很强的抑制活性(IC50 = 14.9 μM)。在进一步的动物实验中,用木糖诱导的大鼠晶状体白内障形成明显受到化合物 1 处理的抑制。